聚合物多孔微针介导的透皮甲福明输送系统:用于增强血糖调节的高剂量持续释放平台
Yan Li1, Sedrati Manar2, Xinxiang Chai2
1School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, China; School of Engineering, Hangzhou Normal University, Hangzhou, Zhejiang 310018, China.
Colloids and surfaces. B, Biointerfaces
|July 5, 2025
概括
新的多孔微针为糖尿病管理提供无痛,持续的高剂量甲胺的输送. 这种通过皮肤的系统有效地控制糖尿病大鼠的血糖水平 (BGLs) 在长时间内没有低血糖风险.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病需要长期控制血糖水平 (BGL).
- 目前的疗法面临的挑战是药物负载能力的持续交付.
- 微针技术为无痛透皮药物输送提供了一个有前途的途径.
研究的目的:
- 开发一种高剂量聚合物多孔微针系统,用于持续输送甲福林.
- 为了优化微针的特性,以便有效地穿透皮肤和释放药物.
- 在糖尿病老鼠模型中评估微针系统的疗效.
主要方法:
- 使用微模板和毛孔引起剂方法制造聚合物多孔微针阵列.
- 调整液体吸收和机械强度,通过改变孔隙引起剂的比率.
- 开发一种药物装载室,用于装载高容量的甲福林 (135.69毫克).
- 在糖尿病大鼠模型中进行体内测试,以评估BGL控制和安全性.
主要成果:
- 成功制备了可调节性质的多孔微针.
- 实现了高药物载荷能力,以持续提供甲胺.
- 在糖尿病大鼠中,已证明有效的皮肤穿刺和稳定的BGL控制在5个周期内长达108小时.
- 在实验期间没有观察到低血糖的风险.
结论:
- 开发的高剂量聚合物多孔微针系统可实现快速反应和持久的甲福林释放.
- 这种透皮药物输送系统是糖尿病持续治疗的潜在候选者.
- 微针技术为治疗需要长期药物输送的慢性疾病提供了一种有前途的方法.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
01:27Insulin Formulations: Types and Delivery
275
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
275
01:06Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269